GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Cash Flow from Investing

CRISPR Therapeutics AG (CRISPR Therapeutics AG) Cash Flow from Investing : $374.6 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, CRISPR Therapeutics AG spent $0.7 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $368.1 Mil on purchasing investments. It gained $287.4 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.0 Mil for other investing activities. In all, CRISPR Therapeutics AG spent $81.5 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


CRISPR Therapeutics AG Cash Flow from Investing Historical Data

The historical data trend for CRISPR Therapeutics AG's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Cash Flow from Investing Chart

CRISPR Therapeutics AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.33 -541.17 -1,035.43 -258.66 374.65

CRISPR Therapeutics AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -175.53 117.83 216.92 121.35 -81.45

CRISPR Therapeutics AG Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

CRISPR Therapeutics AG's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

CRISPR Therapeutics AG's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $374.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CRISPR Therapeutics AG  (NAS:CRSP) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

CRISPR Therapeutics AG's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.7 Mil. It means CRISPR Therapeutics AG spent $0.7 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

CRISPR Therapeutics AG's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.0 Mil. It means CRISPR Therapeutics AG gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

CRISPR Therapeutics AG's purchase of business for the three months ended in Dec. 2023 was $0.0 Mil. It means CRISPR Therapeutics AG spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

CRISPR Therapeutics AG's sale of business for the three months ended in Dec. 2023 was $0.0 Mil. It means CRISPR Therapeutics AG gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

CRISPR Therapeutics AG's purchase of investment for the three months ended in Dec. 2023 was $-368.1 Mil. It means CRISPR Therapeutics AG spent {stock_data.stock.currency_symbol}}368.1 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

CRISPR Therapeutics AG's sale of investment for the three months ended in Dec. 2023 was $287.4 Mil. It means CRISPR Therapeutics AG gained $287.4 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

CRISPR Therapeutics AG's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.0 Mil. It means CRISPR Therapeutics AG paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

CRISPR Therapeutics AG's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.0 Mil. It means CRISPR Therapeutics AG paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

CRISPR Therapeutics AG's cash from other investing activities for the three months ended in Dec. 2023 was $-0.0 Mil. It means CRISPR Therapeutics AG paid $0.0 Mil for other investing activities.


CRISPR Therapeutics AG Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Executives
Samarth Kulkarni officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Raju Prasad officer: Chief Financial Officer CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Phuong Khanh Morrow officer: Chief Medical Officer C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith officer: Chief Financial Officer 29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek officer: Chief Financial Officer 28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak director, officer: Chief Executive Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming director C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
James R. Kasinger officer: General Counsel and Secretary C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
Tony W Ho officer: See Remarks CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni director ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Katherine A High director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104